Form 10-Q Jazz Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
November 7, 2018 8:57 AM ESTCowen analyst Ken Cacciatore lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $200.00 (from $220.00) while maintaining a Outperform rating.
... MoreJazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital
November 7, 2018 8:56 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $203.00 (from $206.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ reported mixed 3Q results with revenue of $469mm below BMO/consensus $478mm/$483mm, and adj. EPS of $3.58 ahead of... More
Jazz Pharmaceuticals (JAZZ) PT Lowered to $184 at RBC Capital
November 7, 2018 7:22 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $184.00 (from $194.00) while maintaining a Outperform rating.
... More